Scouted selects products independently. If you purchase something from our posts, we may earn a small commission. Unless you ...

Truveta’s groundbreaking study analyzing real-world use of GLP-1 receptor agonist (GLP-1 RA) therapies in adults with overweight or obesity has published in JAMA Network Open, offering critical ...

With respect to risks, GLP-1RA use was significantly associated with an increased risk of gastrointestinal disorders, hypotension, syncope, arthritic disorders, drug-induced pancreatitis, and other ...

Several years ago, a little-known drug named Ozempic — previously used only to treat diabetes — emerged as a promising new ...

Clinics in Columbus, Cleveland, Dayton, and Cincinnati have lost their licenses to distribute dangerous drugs after the Ohio ...

In line with trial results, real-world data suggest GLP-1 receptor agonists have certain benefits in patients with moderate to severe chronic kidney disease (CKD).

Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...

Researchers investigate the risk of incident thyroid cancer among patients treated with glucagon-like peptide-1 receptor ...

Websites that sell compounded glucagon-like peptide-1 receptor agonists often partially inform or misinform consumers.

A RECENT population-based analysis has highlighted potential behavioural side effects associated with Glucagon-like peptide 1 ...

An observational analysis has found that the drugs may lower the risk of substance abuse and cognitive issues. But the ...